BTIG Maintains Buy on Oruka Therapeutics, Raises Price Target to $78
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
BTIG analyst Julian Harrison maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $73 to $78.
BTIG analyst Julian Harrison maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $73 to $78.